All Outputs (6)

Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure (2022)
Journal Article
Kazmi, S., Kambhampati, C., Cleland, J., Cuthbert, J., Kazmi, K. S., Pellicori, P., …Clark, A. L. (2022). Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure. ESC Heart Failure, https://doi.org/10.1002/ehf2.14028

Aims: Risk changes with the progression of disease and the impact of treatment. We developed a dynamic risk stratification Markov chain model using artificial intelligence in patients with chronic heart failure (CHF). Methods and results: We describe... Read More about Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure.

Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure (2020)
Journal Article
Samuel, N. A., Cuthbert, J. J., Brown, O. I., Kazmi, S., Cleland, J. G., Rigby, A. S., & Clark, A. L. (2021). Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure. The American journal of cardiology, 139, 57-63. https://doi.org/10.1016/j.amjcard.2020.10.034

Thyroid dysfunction is common in patients with chronic heart failure (CHF), but there is conflicting evidence regarding its prognostic significance. We investigated the relation between thyroid function and prognosis in a large, well characterized co... Read More about Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure.

Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure (2019)
Journal Article
Pellicori, P., Urbinati, A., Kaur, K., Zhang, J., Shah, P., Kazmi, S., …Clark, A. L. (2019). Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure. The American journal of cardiology, https://doi.org/10.1016/j.amjcard.2019.08.018

Heart failure (HF) and atrial fibrillation (AF) commonly co-exist. We aimed to determine the prevalence and incidence of AF in ambulatory patients with HF.

Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance (2018)
Journal Article
Cuthbert, J. J., Pellicori, P., Rigby, A., Pan, D., Kazmi, S., Shah, P., & Clark, A. L. (2018). Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. European journal of heart failure, 20(10), 1426-1435. https://doi.org/10.1002/ejhf.1247

© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology Background: Low serum chloride is common in patients with chronic heart failure (CHF) and is associated with worse outcomes. We investigated the clinical and... Read More about Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance.

Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study (2018)
Journal Article
Sokoreli, I., Pauws, S. C., Steyerberg, E. W., de Vries, G., Riistama, J. M., Tesanovic, A., …Clark, A. L. (2018). Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study. European journal of heart failure, 20(4), 689-696. https://doi.org/10.1002/ejhf.1112

Aims: Psychosocial factors are rarely collected in studies investigating the prognosis of patients with heart failure (HF), and only time to first-event is commonly reported. We investigated the prognostic value of psychosocial factors for predicting... Read More about Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study.

What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? (2017)
Journal Article
Pellicori, P., Urbinati, A., Shah, P., MacNamara, A., Kazmi, S., Dierckx, R., …Clark, A. L. (2017). What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?. European journal of heart failure, 19(6), 768-778. https://doi.org/10.1002/ejhf.788

Aims The PARADIGM-HF trial showed that sacubitril–valsartan, an ARB–neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is uncertain what proportion of patients with HF would be eligible for sacubitril... Read More about What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?.